Medigen Vaccine Biologics Corp (高端疫苗) yesterday reported positive results from an interim analysis of phase 2 trials for its COVID-19 vaccine, saying that the vaccine demonstrated high seroconversion rates and geometric mean titer (GMT) figures.
A seroconversion rate is the percentage of participants in a trial displaying virus-specific immune memory after being given a vaccine, while the GMT measures the level of neutralizing antibody response, Medigen said.
The experimental vaccine has a seroconversion rate of 99.8 percent and its GMT was 662 among the participants aged 20 to 89, while the gauges rose to 99.9 percent and 733 respectively in participants aged 20 to 64, the company said.
Photo: Screen grab from the Internet
No participants have shown severe adverse reactions, it said.
Only 0.7 percent of participants who were given experimental vaccines had a fever, compared with 0.4 percent in those who received a placebo, while among those who received the vaccine 27.6 percent had muscle soreness and 36 percent felt tired, compared with 16.6 percent and 29.7 percent respectively for those who were given a placebo, it said.
“It would be the regulator that decides if our experimental vaccine has good efficacy, but I personally found the results — the seroconversion rates and the GMT figures — optimistic,” Medigen chief executive officer Charles Chen (陳燦堅) said.
“And it is very safe,” Chen added.
The company will apply to the Food and Drug Administration for emergency use authorization as soon as possible, he said.
However, asked which COVID-19 vaccine developed outside Taiwan that has been granted emergency use authorization Medigen’s experimental vaccine might be compared to, the company said it has not reached a conclusion.
“An estimate needs to be done scientifically. We can conduct an immune-bridging study to compare the antibody levels in people who are given different COVID-19 vaccines, and the WHO is also trying to establish common standards for COVID-19 vaccines,” Medigen head of development Lien Chia-en (連加恩) said.
For example, Medigen’s clinical trial result of a GMT of 662 could be converted into international units (IU) and foreign vaccine developers could do likewise to enable international comparison, Lien said.
“However, this would take some time and other companies have not disclosed their data in IU yet,” he said.
Amid discussions over whether locally developed COVID-19 vaccines would be better than foreign vaccines, Chen and Medigen spokesman Leo Lee (李思賢) said that they are confident in their product and they and their families would get Medigen’s vaccine.
Medigen is to conduct phase 3 trials for its vaccine to earn approval from foreign regulators and it aims to conduct the tests in Europe, Chen said, adding that the UK recently allowed a French company to conduct phase 3 human testing there.
It costs about US$10,000 per participant in phase 3 trials, so the costs would be enormous if Medigen recruited 30,000 participants, Chen said.
BREAKING RECORDS: Kuo Hsing-chun’s snatch, clean and jerk, and combined lifts were all Olympic records, although well off her combined world record Taiwanese weightlifter Kuo Hsing-chun (郭婞淳) yesterday completed her elusive quest for Olympic gold, clinching Taiwan’s first win at the Tokyo Games as she set Olympic records in the women’s under-59kg weight class. Kuo, who has not lost a major competition in her weight class since the 2016 Olympics in Rio de Janeiro, where she was hampered by injury and finished third, finally chased down the gold medal that had long remained just out of her grasp. The 27-year-old finished with a combined lift of 236kg — 103kg in the snatch and 133kg in the clean and jerk — 21kg more
NEXT ROUND: About 1.44 million people who have registered online to receive the AstraZeneca vaccine are to get text messages today to book a vaccine appointment Strict border control measures, including a ban on foreign nationals entering or transiting through Taiwan, are to continue, the Central Epidemic Command Center (CECC) said yesterday, as it reported 10 locally transmitted COVID-19 infections and no deaths. Minister of Health and Welfare Chen Shih-chung (陳時中), who heads the center, said five of the cases tested positive during isolation or upon ending it. The sources of infection of eight cases have been identified, one remains unclear and one is under investigation, he said, adding that 87.8 percent of the people infected with COVID-19 since May 11 have been released from isolation. Chen said an
NO ‘ONE CHINA’ LIE: The appropriations act passed the US House of Representatives with a vote of 217-212, but still needs Senate approval and the president’s signature The US House of Representatives on Wednesday passed a foreign assistance spending bill with an amendment forbidding that funds be used to create, procure or display maps depicting Taiwan as part of the People’s Republic of China. The amendment was introduced by five Republican representatives — Tom Tiffany, Steve Chabot, Scott Perry, Kat Cammack and Mike Gallagher — and passed unanimously in a bundle with a dozen other amendments. “This is a common sense measure,” Tiffany said, speaking on the House floor on Wednesday. “As we all know, Taiwan has never been part of communist China. The Taiwanese people elect their
THE HOME TEAM: DPP Legislator Kao Chia-yu said she canceled her booking for an AstraZeneca shot as soon as she heard that the Medigen vaccine was an option President Tsai Ing-wen (蔡英文) yesterday said that she would get inoculated with the COVID-19 vaccine manufactured by Taiwan-based Medigen Vaccine Biologics Corp (高端疫苗). Tsai wrote on Facebook that she had registered for her first vaccine dose using the national online COVID-19 vaccination booking system, which allows people to indicate their preferred vaccine brand and to make an appointment when the shot becomes available. Tsai said that she opted for the Medigen vaccine — one of three now available on the system, along with the AstraZeneca and Moderna vaccines — even though Medigen has yet to deliver any doses or provide a